Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - thelancet.com
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …
被引用次数：136 相关文章

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-
platinum-cetuximab) showed promising results, with a median overall survival of 14· 0 …
[PDF] gortec.net

[PDF][PDF] Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - 2021 - gortec.net
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette… - The Lancet …, 2021 - europepmc.org
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-
platinum-cetuximab) showed promising results, with a median overall survival of 14· 0 …

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - thelancet.com
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - Elsevier
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

[引用][C] Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette… - The Lancet …, 2021 - produccioncientifica.usal.es
Background: Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …
[PDF] gortec.net

[PDF][PDF] Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - 2021 - gortec.net
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …
[PDF] unicancer.fr

[PDF][PDF] Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - Lancet …, 2021 - icm.unicancer.fr
Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–
platinum–cetuximab) showed promising results, with a median overall survival of 14· 0 …

[引用][C] Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck …

J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - cir.nii.ac.jp
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line
treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC …